The Experts below are selected from a list of 258 Experts worldwide ranked by ideXlab platform

Parminder K Judge - One of the best experts on this subject based on the ideXlab platform.

  • Biliary Tract and liver complications in polycystic kidney disease
    Journal of The American Society of Nephrology, 2017
    Co-Authors: Parminder K Judge, Charlie H S Harper, Benjamin C Storey, Richard Haynes, Martin J Wilcock, Natalie Staplin
    Abstract:

    Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary Tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with Biliary Tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998-2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for Biliary Tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for Biliary Tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with Biliary Tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for Biliary Tract disease were larger for men than women (heterogeneity P<0.001), but RRs for serious liver complications appeared higher in women (heterogeneity P<0.001). Absolute excess risk of Biliary Tract disease associated with ADPKD was larger than that for serious liver disease, cerebral aneurysms, and inguinal hernias but less than that for urinary Tract infections. Overall, Biliary Tract disease seems to be a distinct and important extrarenal complication of ADPKD.

  • Biliary Tract and liver complications in polycystic kidney disease
    Journal of The American Society of Nephrology, 2017
    Co-Authors: Parminder K Judge, Benjamin C Storey, Richard Haynes, Martin J Wilcock, Natalie Staplin, Raph Goldacre, Colin Baigent
    Abstract:

    Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary Tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with Biliary Tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998–2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for Biliary Tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for Biliary Tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with Biliary Tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for Biliary Tract disease were larger for men than women (heterogeneity P P

Richard Haynes - One of the best experts on this subject based on the ideXlab platform.

  • Biliary Tract and liver complications in polycystic kidney disease
    Journal of The American Society of Nephrology, 2017
    Co-Authors: Parminder K Judge, Charlie H S Harper, Benjamin C Storey, Richard Haynes, Martin J Wilcock, Natalie Staplin
    Abstract:

    Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary Tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with Biliary Tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998-2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for Biliary Tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for Biliary Tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with Biliary Tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for Biliary Tract disease were larger for men than women (heterogeneity P<0.001), but RRs for serious liver complications appeared higher in women (heterogeneity P<0.001). Absolute excess risk of Biliary Tract disease associated with ADPKD was larger than that for serious liver disease, cerebral aneurysms, and inguinal hernias but less than that for urinary Tract infections. Overall, Biliary Tract disease seems to be a distinct and important extrarenal complication of ADPKD.

  • Biliary Tract and liver complications in polycystic kidney disease
    Journal of The American Society of Nephrology, 2017
    Co-Authors: Parminder K Judge, Benjamin C Storey, Richard Haynes, Martin J Wilcock, Natalie Staplin, Raph Goldacre, Colin Baigent
    Abstract:

    Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary Tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with Biliary Tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998–2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for Biliary Tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for Biliary Tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with Biliary Tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for Biliary Tract disease were larger for men than women (heterogeneity P P

Benjamin C Storey - One of the best experts on this subject based on the ideXlab platform.

  • Biliary Tract and liver complications in polycystic kidney disease
    Journal of The American Society of Nephrology, 2017
    Co-Authors: Parminder K Judge, Charlie H S Harper, Benjamin C Storey, Richard Haynes, Martin J Wilcock, Natalie Staplin
    Abstract:

    Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary Tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with Biliary Tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998-2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for Biliary Tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for Biliary Tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with Biliary Tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for Biliary Tract disease were larger for men than women (heterogeneity P<0.001), but RRs for serious liver complications appeared higher in women (heterogeneity P<0.001). Absolute excess risk of Biliary Tract disease associated with ADPKD was larger than that for serious liver disease, cerebral aneurysms, and inguinal hernias but less than that for urinary Tract infections. Overall, Biliary Tract disease seems to be a distinct and important extrarenal complication of ADPKD.

  • Biliary Tract and liver complications in polycystic kidney disease
    Journal of The American Society of Nephrology, 2017
    Co-Authors: Parminder K Judge, Benjamin C Storey, Richard Haynes, Martin J Wilcock, Natalie Staplin, Raph Goldacre, Colin Baigent
    Abstract:

    Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary Tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with Biliary Tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998–2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for Biliary Tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for Biliary Tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with Biliary Tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for Biliary Tract disease were larger for men than women (heterogeneity P P

Natalie Staplin - One of the best experts on this subject based on the ideXlab platform.

  • Biliary Tract and liver complications in polycystic kidney disease
    Journal of The American Society of Nephrology, 2017
    Co-Authors: Parminder K Judge, Charlie H S Harper, Benjamin C Storey, Richard Haynes, Martin J Wilcock, Natalie Staplin
    Abstract:

    Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary Tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with Biliary Tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998-2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for Biliary Tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for Biliary Tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with Biliary Tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for Biliary Tract disease were larger for men than women (heterogeneity P<0.001), but RRs for serious liver complications appeared higher in women (heterogeneity P<0.001). Absolute excess risk of Biliary Tract disease associated with ADPKD was larger than that for serious liver disease, cerebral aneurysms, and inguinal hernias but less than that for urinary Tract infections. Overall, Biliary Tract disease seems to be a distinct and important extrarenal complication of ADPKD.

  • Biliary Tract and liver complications in polycystic kidney disease
    Journal of The American Society of Nephrology, 2017
    Co-Authors: Parminder K Judge, Benjamin C Storey, Richard Haynes, Martin J Wilcock, Natalie Staplin, Raph Goldacre, Colin Baigent
    Abstract:

    Polycystic liver disease is a well described manifestation of autosomal dominant polycystic kidney disease (ADPKD). Biliary Tract complications are less well recognized. We report a 50-year single-center experience of 1007 patients, which raised a hypothesis that ADPKD is associated with Biliary Tract disease. We tested this hypothesis using all England Hospital Episode Statistics data (1998–2012), within which we identified 23,454 people with ADPKD and 6,412,754 hospital controls. Hospitalization rates for Biliary Tract disease, serious liver complications, and a range of other known ADPKD manifestations were adjusted for potential confounders. Compared with non-ADPKD hospital controls, those with ADPKD had higher rates of admission for Biliary Tract disease (rate ratio [RR], 2.24; 95% confidence interval [95% CI], 2.16 to 2.33) and serious liver complications (RR, 4.67; 95% CI, 4.35 to 5.02). In analyses restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated substantially, but ADPKD remained associated with Biliary Tract disease (RR, 1.19; 95% CI, 1.08 to 1.31) and perhaps with serious liver complications (RR, 1.15; 95% CI, 0.98 to 1.33). The ADPKD versus non-ADPKD RRs for Biliary Tract disease were larger for men than women (heterogeneity P P

Takuji Okusaka - One of the best experts on this subject based on the ideXlab platform.

  • Targeted Therapy for Biliary Tract Cancer
    Cancers, 2011
    Co-Authors: Junji Furuse, Takuji Okusaka
    Abstract:

    It is necessary to establish effective chemotherapy to improve the survival of patients with Biliary Tract cancer, because most of these patients are unsuitable candidates for surgery, and even patients undergoing curative surgery often have recurrence. Recently, the combination of cisplatin plus gemcitabine was reported to show survival benefits over gemcitabine alone in randomized clinical trials conducted in the United Kingdom and Japan. Thus, the combination of cisplatin plus gemcitabine is now recognized as the standard therapy for unresectable Biliary Tract cancer. One of the next issues that need to be addressed is whether molecular targeted agents might also be effective against Biliary Tract cancer. Although some targeted agents have been investigated as monotherapy for first-line chemotherapy, none were found to exert satisfactory efficacy. On the other hand, monoclonal antibodies such as bevacizumab and cetuximab have also been investigated in combination with a gemcitabine-based regimen and have been demonstrated to show promising activity. Furthermore, clinical trials using new targeted agents for Biliary Tract cancer are also proposed. This cancer is a relatively rare and heterogeneous tumor consisting of cholangiocarcinoma and gallbladder carcinoma. Therefore, a large randomized clinical trial is necessary to confirm the efficacy of chemotherapy, and international collaboration is important.

  • Chemotherapy for Biliary Tract cancer in Japan
    Seminars in Oncology, 2002
    Co-Authors: Takuji Okusaka
    Abstract:

    AbsTract The incidence of Biliary Tract cancer has increased markedly in Japan over the past several decades and ranks as the sixth leading cause of cancer death. Currently, there is no standard chemotherapy for Biliary Tract cancer. Early phase investigation of cisplatin and cisplatin/epirubicin/5-fluorouracil yielded disappointing results in this setting. Gemcitabine is currently approved for use in the treatment of non–small cell lung cancer and pancreatic cancer in Japan. Based on the single-agent activity of gemcitabine in Biliary Tract cancer in other locales combined with the drug's established safety profile, gemcitabine is currently being evaluated as single-agent therapy in the treatment of advanced Biliary Tract cancer patients in Japan. Semin Oncol 29 (suppl 20):51-53. Copyright 2002, Elsevier Science (USA). All rights reserved.

  • Chemotherapy for Biliary Tract cancer in Japan.
    Seminars in oncology, 2002
    Co-Authors: Takuji Okusaka
    Abstract:

    The incidence of Biliary Tract cancer has increased markedly in Japan over the past several decades and ranks as the sixth leading cause of cancer death. Currently, there is no standard chemotherapy for Biliary Tract cancer. Early phase investigation of cisplatin and cisplatin/epirubicin/5-fluorouracil yielded disappointing results in this setting. Gemcitabine is currently approved for use in the treatment of non-small cell lung cancer and pancreatic cancer in Japan. Based on the single-agent activity of gemcitabine in Biliary Tract cancer in other locales combined with the drug's established safety profile, gemcitabine is currently being evaluated as single-agent therapy in the treatment of advanced Biliary Tract cancer patients in Japan.